| First Author | García-Cao I | Year | 2005 |
| Journal | EMBO Rep | Volume | 6 |
| Issue | 6 | Pages | 577-83 |
| PubMed ID | 15877079 | Mgi Jnum | J:98835 |
| Mgi Id | MGI:3580028 | Doi | 10.1038/sj.embor.7400421 |
| Citation | Garcia-Cao I, et al. (2005) Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 6(6):577-83 |
| abstractText | The proapoptotic protein encoded by Par4 (prostate apoptosis response 4) has been implicated in tumour suppression, particularly in the prostate. We report here that Par4-null mice are prone to develop tumours, both spontaneously and on carcinogenic treatment. The endometrium and prostate of Par4-null mice were particularly sensitive to the development of proliferative lesions. Most (80%) Par4-null females presented endometrial hyperplasia by 9 months of age, and a significant proportion (36%) developed endometrial adenocarcinomas after 1 year of age. Similarly, Par4-null males showed a high incidence of prostate hyperplasia and prostatic intraepithelial neoplasias, and were extraordinarily sensitive to testosterone-induced prostate hyperplasia. Finally, the uterus and prostate of young Par4-null mice have increased levels of the apoptosis inhibitor XIAP (X-chromosome-linked inhibitor of apoptosis), supporting the previously proposed function of Par4 as an inhibitor of the zetaPKC (atypical protein kinase)-NF-kappaB (nuclear factor-kappaB)-XIAP pathway. These data show that Par4 has an important role in tumour suppression, with a particular relevance in the endometrium and prostate. |
